Compelling indications jnc 7 pdf

2003 JNC 7 HTN treatment algorithm JNC 7. JAMA 2003. Lifestyle modi?cations Goal blood pressure < 140/90 mmHg <130/80 mmHg with diabetes or CKD Initial drug choices Without compelling indications With compelling indications Stage 1 HTN SBP 140-159 DBP 90-99 Stage 2 HTN SBP > 160 DBP > 100 Drug(s) for compelling indications Diuretics; consider As in JNC 7, the JNC 8 guidelines also recommend lifestyle changes as an important component of therapy. Lifestyle interventions include use of the Dietary Approaches to Stop Hypertension (DASH) eating plan, weight loss, reduction in sodium intake to less than 2.4 grams per day, and at least 30 minutes of aerobic activity most days of the week. THE EIGHTH JOINT NATIONAL COMMITTEE (JNC 8) The new guideline has simpli? ed the treatment of hypertension. Patients are categorized ac-cording to age and the presence of diabetes (DM) or/and chronic kidney disease (CKD). De? ni-tions of hypertension and prehypertension are not addressed, but thresholds for pharmaco-logic treatment are Drug choice for patients who have stage 2 hypertension and compelling indications? drugs for compelling indications According to JNC-7, what is the blood pressure goal for CKD and DM patients with HTN? Hipertension arterial jnc 7 s for compelling indications. UKPDS did show that treatment in the lower goal BP group was associated with a significantly lower hipertension arterial jnc 7 of stroke, hipertension arterial jnc 7 failure, diabetes-related end points, and deaths related to diabetes. 1. JAMA. 2003 May 21;289(19):2560-72. Epub 2003 May 14. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. In contrast to JNC 7 where thiazides were recommended to be the initial choice in patients without compelling indications, no such recommendation has been made in JNC 8. One major difference was the methodology by which committee reached these recommendations. For the relatively large number of patients who have compelling indications, it was possible for the members of JNC 7 to side-step the NHLBF's diuretics-first dictum (though, of course, in many cases the addition of a low-dose diuretic will eventually be considered to help optimize blood pressure control). - The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Dr. Chobanian has received honoraria for serving as a speaker from Monarch, Wyeth, Astra- Zeneca, Solvay, and Bristol-Myers Squibb. The laminated card includes at-a-glance versions of essential JNC 7 evaluation changes, new treatment algorithm, and compelling indications for individual drug classes. Get this card for those who don't have time to stop to consult the Evidence Report during treatment hours. Guidelines for Management of High Blood Pressure in Adults In 2014, panel members of the Eighth Joint National Committee published the results of their evidence review and deliberations about the prevention, detection, evaluation, and treatment of high blood pressure. Past JNC Reports JNC 7 PDF | "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure" provides a new guideline for hypertension prevention and PDF | "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure" provide